Anti-(human Interleukin 23) (human Monoclonal Medi2070 Heavy Chain) Uses, Dosage, Side Effects and more
Anti-(human Interleukin 23) (human Monoclonal Medi2070 Heavy Chain) is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study of Anti-(human Interleukin 23) (human Monoclonal Medi2070 Heavy Chain) in Participants With Moderately to Severely Active Crohn's Disease).
| Trade Name | Anti-(human Interleukin 23) (human Monoclonal Medi2070 Heavy Chain) |
| Generic | Brazikumab |
| Brazikumab Other Names | Brazikumab, Immunoglobulin g2, anti-(human interleukin 23) (human monoclonal medi2070 heavy chain), disulfide with human monoclonal medi2070 .lambda.-chain, dimer |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
